What this study adds
- This was the first study to determined that Cystatin C,
myeloperoxidase and dosage forms were important factors influencing
MPA pharmacokinetics in pediatric AAN.
- Cystatin C had an advantage in predicting CL of MPA.
- The combined effects of myeloperoxidase and renal function resulted in
a 6-fold range in MPA dose.